We read with interest the recent publication of a prospective randomized trial of amifostine cytoprotection in myeloma patients receiving high-dose melphalan by the Australian Leukemia and Lymphoma Group. 1 A few other studies have also shown similar cytoprotective benefit. [2] [3] [4] However, our limited nonrandomized, retrospective experience suggests lack of beneficial effect of amifostine in autologous stem cell transplantation (ASCT).
The study group (Group A) consisted of seven patients with myeloma and two with Hodgkin The control group (Group B) consisted of nine patients (seven myeloma and two Hodgkin's disease) aged 41 years (range, 21-59 years). There were six male and three female subjects in Group A, and seven male and two female subjects in Group B. All patients had received prior chemotherapy, while three patients had also received prior radiation. Pre-transplant glomerular filtration rate (GFR) was low in seven patients in group A and five patients in group B. Pulmonary function tests were abnormal in two and one patient in groups A and B, respectively. Blood biochemistry and cardiac function were normal in all patients. The median serum albumin and serum creatinine levels in study population were 3.5 g/dl and 0.7 mg/dl, while that in control group were 4.0 g/dl and 0.8 mg/dl, respectively. The median CD34 þ cell dose in study arm was 2.6 Â 10 6 /kg and 2.2 Â 10 6 /kg in the control arm. Group A patients received amifostine at the dose of 910 mg/m 2 as a short i.v. infusion over 15 min, half an hour prior to melphalan.
Hematological and nonhematological toxicity, engraftment kinetics, need for supportive care including blood products, duration of growth factors, antibiotics, opioid analgesics and parenteral nutrition, and the duration of hospitalization was studied. Toxicity was graded according to the NCI toxicity grading. Amifostine infusion-related adverse events were seen in 44% of patients (bradycardia ¼ one, drop in blood pressure ¼ one, vomiting ¼ two), none of which required discontinuation of the drug. In contrast to the recent publication, 1 we did not find any reduction in the severity and/or duration of mucositis nor a benefit in other parameters studied with amifostine (Tables  1 and 2 ). In fact, hospital stay was significantly increased in the amifostine arm (P ¼ 0.04) with a resultant increase in cost. It is difficult to explain the discrepancy between our findings and those from other studies.
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